Syn2bio Spolka Akcyjna

As of June 30, 2026, Syn2bio Spolka Akcyjna carries a market capitalization of 422.49M, placing it among publicly traded companies globally. Its enterprise value stands at 422.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Syn2bio Spolka Akcyjna has 8.73M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Syn2bio Spolka Akcyjna maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.70, indicating elevated leverage, while an interest coverage ratio of -2,901.48 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Syn2bio Spolka Akcyjna recorded an income tax benefit of -1,989.47 rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

These figures are as of the close on October 22, 2026.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Syn2bio Spolka Akcyjna holds 18,965.09 in cash and equivalents against 571.96 in total debt, resulting in a net debt position of -18,965.09. Total book value stands at 33,599.52, with working capital of 10,849.62 providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -58.55 in capital expenditures, free cash flow totaled -6,990.76 - equivalent to 0.00 per share.